Andrew Schiermeier
Chief Executive Officer bei AvenCell Therapeutics, Inc.
Profil
Andrew D. Schiermeier ist Mitglied des Vorstands von Kynan Pharmaceuticals und Chief Operating Officer von Intellia Therapeutics, Inc. In seiner früheren Karriere war er Chief Operating Officer bei Aura Biosciences, Inc. und Senior CP & Head-Oncology Business bei der Merck KGaA. Er erhielt einen MBA vom College des Ingenieurs, einen Doktortitel von der Harvard University und einen Graduiertenabschluss von der Stanford University.
Aktive Positionen von Andrew Schiermeier
| Unternehmen | Position | Beginn |
|---|---|---|
| Kynan Pharmaceuticals | Director/Board Member | - |
AvenCell Therapeutics, Inc.
 AvenCell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AvenCell Therapeutics, Inc. is a biopharmaceutical company that develops immunotherapies to treat cancers. The private company is based in Cambridge, MA and has subsidiaries in Germany. Andrew D. Schiermeier has been the CEO of the company since 2021. | Chief Executive Officer | 01.08.2021 |
Regel Therapeutics Inc.
 Regel Therapeutics Inc. BiotechnologyHealth Technology Regel Therapeutics Inc. develops a proprietary technology platform related to gene therapy. The company is based in Cambridge, MA. The company was founded in 2020 by Navneet Matharu, Jordane Dimidschstein, Steven B. Ruchefsky, Michael Jasulavic, Orrin Devinsky. Steven B. Ruchefsky has been the CEO since 2020. | Director/Board Member | - |
Ehemalige bekannte Positionen von Andrew Schiermeier
| Unternehmen | Position | Ende |
|---|---|---|
| INTELLIA THERAPEUTICS, INC. | Chief Operating Officer | 21.06.2021 |
| MERCK KGAA | Corporate Officer/Principal | 01.01.2016 |
| AURA BIOSCIENCES, INC. | Chief Operating Officer | 01.05.2013 |
Ausbildung von Andrew Schiermeier
| Harvard University | Doctorate Degree |
| Stanford University | Graduate Degree |
| College des Ingenieurs | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| MERCK KGAA | Health Technology |
| AURA BIOSCIENCES, INC. | Health Technology |
| INTELLIA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
| Kynan Pharmaceuticals | |
AvenCell Therapeutics, Inc.
AvenCell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AvenCell Therapeutics, Inc. is a biopharmaceutical company that develops immunotherapies to treat cancers. The private company is based in Cambridge, MA and has subsidiaries in Germany. Andrew D. Schiermeier has been the CEO of the company since 2021. | Health Technology |
Regel Therapeutics Inc.
Regel Therapeutics Inc. BiotechnologyHealth Technology Regel Therapeutics Inc. develops a proprietary technology platform related to gene therapy. The company is based in Cambridge, MA. The company was founded in 2020 by Navneet Matharu, Jordane Dimidschstein, Steven B. Ruchefsky, Michael Jasulavic, Orrin Devinsky. Steven B. Ruchefsky has been the CEO since 2020. | Health Technology |
